Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
J Vet Sci ; 16(1): 1-9, 2015.
Article in English | MEDLINE | ID: mdl-24962420

ABSTRACT

In the present study, the detrimental effect of ß-emission on pig skin was evaluated. Skin injury was modeled in mini-pigs by exposing the animals to 50 and 100 Gy of ß-emission delivered by (166)Ho patches. Clinicopathological and immunohistochemical changes in exposed skin were monitored for 18 weeks after ß-irradiation. Radiation induced desquamation at 2~4 weeks and gradual repair of this damage was evident 6 weeks after irradiation. Changes in basal cell density and skin depth corresponded to clinically relevant changes. Skin thickness began to decrease 1 week after irradiation, and the skin was thinnest 4 weeks after irradiation. Skin thickness increased transiently during recovery from irradiation-induced skin injury, which was evident 6~8 weeks after irradiation. Epidermal expression of nuclear factor-kappa B (NF-κB) differed significantly between the untreated and irradiated areas. One week after irradiation, cyclooxygenase-2 (COX-2) expression was mostly limited to the basal cell layer and scattered among these cells. High levels of COX-2 expression were detected throughout the full depth of the skin 4 weeks after irradiation. These findings suggest that NF-κB and COX-2 play roles in epidermal cell regeneration following ß-irradiation of mini-pig skin.


Subject(s)
Cyclooxygenase 2/metabolism , Holmium , NF-kappa B/metabolism , Radiation Injuries, Experimental/veterinary , Skin/radiation effects , Animals , Cyclooxygenase 2/genetics , Male , NF-kappa B/genetics , Radiation Injuries, Experimental/metabolism , Skin/metabolism , Swine , Swine, Miniature
2.
J Feline Med Surg ; 11(12): 977-84, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19540785

ABSTRACT

The development of a protocol to reproducibly induce thymic atrophy, as occurs in feline immunodeficiency virus (FIV) infection and other immunosuppressive diseases, and to consistently estimate thymic volume, provides a valuable tool in the search of innovative and novel therapeutic strategies. Magnetic resonance imaging (MRI) using the short tau inversion recovery (STIR) technique, with fat suppression properties, was determined to provide an optimized means of locating, defining, and quantitatively estimating thymus volume in young cats. Thymic atrophy was induced in four, 8-10-week-old kittens with a single, directed 500 cGy dose of 6 MV X-rays from a clinical linear accelerator, and sequential MR images of the cranial mediastinum were collected at 2, 7, 14, and 21 days post irradiation (PI). Irradiation induced a severe reduction in thymic volume, which was decreased, on average, to 47% that of normal, by 7 days PI. Histopathology confirmed marked, diffuse thymic atrophy, characterized by reduced thymic volume, decreased overall cellularity, increased apoptosis, histiocytosis, and reduced distinction of the corticomedullary junction, comparable to that seen in acute FIV infection. Beginning on day 7 PI, thymic volumes rebounded slightly and continued to increase over the following 14 days, regaining 3-35% of original volume. These findings demonstrate the feasibility and advantages of using this non-invasive, in vivo imaging technique to measure and evaluate changes in thymic volume in physiologic and experimental situations. All experimental protocols in this study were approved by the Institutional Animal Care and Use Committee (IACUC) at Auburn University.


Subject(s)
Disease Models, Animal , Feline Acquired Immunodeficiency Syndrome/pathology , Magnetic Resonance Imaging/veterinary , Radiation Injuries, Experimental/pathology , Radiation Injuries, Experimental/veterinary , Thymus Gland/pathology , Animals , Atrophy/veterinary , Cats , Female , Male , Reproducibility of Results , Thymus Gland/radiation effects
3.
Invest Ophthalmol Vis Sci ; 50(7): 3482-94, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19234347

ABSTRACT

PURPOSE: AP-1 has been proposed as a key intermediate linking exposure to light and photoreceptor cell death in rodent light-damage models. Inhibition of AP-1 associated with steroid administration also prevents light damage. In this study the role of steroids in inhibiting AP-1 activation and/or in preventing photoreceptor degeneration was examined in the rhodopsin mutant dog model. METHODS: The dogs were dark adapted overnight, eyes dilated with mydriatics; the right eye was light occluded and the fundus of the left eye photographed ( approximately 15-17 overlapping frames) with a fundus camera. For biochemical studies, the dogs remained in the dark for 1 to 3 hours after exposure. Twenty-four hours before exposure to light, some dogs were treated with systemic dexamethasone or intravitreal/subconjunctival triamcinolone. AP-1 DNA-binding activity was determined by electrophoresis mobility shift assay (EMSA) and phosphorylation of c-Fos and activation of ERK1/2 were determined by immunoblot analyses. The eyes were collected 1 hour and 2 weeks after exposure to light, for histopathology and immunocytochemistry. RESULTS: Inhibition of AP-1 activation, and phosphorylation of ERK1/2 and c-Fos were found after dexamethasone treatment in light-exposed T4R RHO mutant dog retinas. In contrast, increased AP-1 activity and phosphorylation of c-Fos and ERK1/2 were found in triamcinolone-treated mutant retinas. Similar extensive rod degeneration was found after exposure to light with or without treatment, and areas with surviving photoreceptor nuclei consisted primarily of cones. Only with systemic dexamethasone did the RPE cell layer remain. CONCLUSIONS: Intraocular or systemic steroids fail to prevent light-induced photoreceptor degeneration in the T4R RHO dog retina. Finding that systemic dexamethasone prevents AP-1 activation, yet does not prevent retinal light damage, further supports the hypothesis that AP-1 is not the critical player in the cell-death signal that occurs in rods.


Subject(s)
Dog Diseases/prevention & control , Glucocorticoids/administration & dosage , Light/adverse effects , Photoreceptor Cells, Vertebrate/radiation effects , Radiation Injuries, Experimental/veterinary , Retinal Degeneration/veterinary , Rhodopsin/genetics , Transcription Factor AP-1/antagonists & inhibitors , Animals , Dark Adaptation , Dexamethasone/administration & dosage , Disease Models, Animal , Dog Diseases/genetics , Dog Diseases/pathology , Dogs , Electrophoretic Mobility Shift Assay , Fluorescent Antibody Technique, Indirect , Immunoblotting , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Mutation , Oligonucleotide Probes , Phosphorylation , Photoreceptor Cells, Vertebrate/pathology , Proto-Oncogene Proteins c-fos/metabolism , Radiation Injuries, Experimental/genetics , Radiation Injuries, Experimental/pathology , Radiation Injuries, Experimental/prevention & control , Retinal Degeneration/genetics , Retinal Degeneration/pathology , Retinal Degeneration/prevention & control , Transcription Factor AP-1/genetics , Transcription Factor AP-1/metabolism , Triamcinolone Acetonide/administration & dosage
4.
Invest Ophthalmol Vis Sci ; 48(11): 4907-18, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17962438

ABSTRACT

PURPOSE: The T4R RHO mutant dog retina shows retinal degeneration with exposures to light comparable to those used in clinical eye examinations of patients. To define the molecular mechanisms of the degeneration, AP-1 DNA-binding activity, composition, posttranslational modification of the protein complex, and modulation of ERK/MAPK signaling pathways were examined in light-exposed mutant retinas. METHODS: Dark-adapted retinas were exposed to short-duration light flashes from a retinal camera used clinically for retinal photography and were collected at different time points after exposure. Electrophoretic mobility shift assay (EMSA), supershift EMSA, Western blot analysis, and immunocytochemistry were used to examine AP-1 signaling. RESULTS: Exposure to light of mutant retinas significantly increased AP-1 DNA-binding activity by 1 hour after exposure, and levels remained elevated for 6 hours. Shielded mutant retinas had similar AP-1 levels to shielded or exposed wild-type retinas. The parallel phosphorylation of c-Fos and activation of ERK1/2 was detected only in exposed mutant retinas. Exposure to light changed the composition of the AP-1 protein complex in the mutant retina from c-Jun/Fra-1/c-Fos to JunB/c-Fos. Immunohistochemistry showed that the components of activated AP-1 (JunB, and phosphorylated c-Fos, and phosphorylated ERK1/2 isoforms) were localized in Müller cells. CONCLUSIONS: The inner nuclear layer/Müller cell localization of the key proteins induced by light exposure raises the question of the direct involvement of AP-1 in mediating photoreceptor cell death in this model of autosomal dominant retinitis pigmentosa.


Subject(s)
Dog Diseases/genetics , Gene Expression Regulation , Photoreceptor Cells, Vertebrate/radiation effects , Radiation Injuries, Experimental/veterinary , Retinal Degeneration/veterinary , Rhodopsin/genetics , Transcription Factor AP-1/genetics , Animals , Blotting, Western , Cell Death , Cell Survival , DNA/metabolism , Dog Diseases/metabolism , Dog Diseases/pathology , Dogs , Electrophoretic Mobility Shift Assay , Immunohistochemistry , Light , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Phosphorylation , Photoreceptor Cells, Vertebrate/metabolism , Photoreceptor Cells, Vertebrate/pathology , Proto-Oncogene Proteins c-fos/metabolism , Radiation Injuries, Experimental/genetics , Radiation Injuries, Experimental/metabolism , Radiation Injuries, Experimental/pathology , Retinal Degeneration/genetics , Retinal Degeneration/metabolism , Retinal Degeneration/pathology , Signal Transduction/genetics , Transcription Factor AP-1/metabolism
5.
Int J Radiat Biol ; 83(10): 653-63, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17729160

ABSTRACT

PURPOSE: To examine the protective effects of histamine on intestinal damage produced by gamma-radiation. MATERIALS AND METHODS: 56 mice were divided into 4 groups. Histamine and Histamine-10 Gy groups received a daily subcutaneous histamine injection (0.1 mg/kg) starting 20 hours before irradiation and continued until the end of the experimental period; the untreated group received saline. Histamine-10 Gy and untreated-10 Gy groups were irradiated with a single dose on whole-body using Cesium-137 source (7 Gy/min) and were sacrificed 3 days after irradiation. Small intestine was removed, fixed and stained with hematoxylin and eosin. The number of intestinal crypts per circumference, and other histological characteristics of intestinal cells were evaluated. We further determined by immunohistochemistry the expression of proliferating cell nuclear antigen (PCNA), Bax, Bcl-2 (pro- and anti-apoptotic protein, respectively), antioxidant enzymes (Superoxide dismutase (SOD), Catalase and Glutathione peroxidase), histamine content and apoptosis by terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate biotin nick end labeling (TUNEL) assay. Cells in the S phase of the cell cycle were identified by immunohistochemical detection of 5-bromo-2'-deoxyuridine (BrdU) incorporation. RESULTS: Histamine treatment reduced mucosal atrophy, edema and preserved villi, crypts and nuclear and cytoplasmic characteristics of small intestine after radiation exposure. Additionally, histamine treatment increased PCNA expression and the BrdU-positive cell number, histamine content, decreased the number of apoptotic cells and significantly increased Catalase and copper-zinc-containing SOD of irradiated mice. CONCLUSIONS: Histamine prevents radiation-induced toxicity by increasing proliferation of damaged intestinal mucosa and suppressing apoptosis that was associated with an increase in SOD and Catalase levels. This effect might be of clinical value in patients undergoing radiotherapy.


Subject(s)
Apoptosis/drug effects , Cell Proliferation/drug effects , Cesium Isotopes/metabolism , Histamine/administration & dosage , Intestine, Small/drug effects , Radiation Injuries, Experimental/prevention & control , Animals , Cell Nucleus/pathology , Cytoplasm/pathology , Edema/pathology , Histamine/pharmacology , Immunohistochemistry , Injections, Subcutaneous , Intestinal Diseases/drug therapy , Intestinal Diseases/pathology , Intestinal Diseases/radiotherapy , Intestine, Small/pathology , Intestine, Small/radiation effects , Mice , Mice, Nude , Peroxidases/metabolism , Proliferating Cell Nuclear Antigen/metabolism , Radiation Injuries, Experimental/drug therapy , Radiation Injuries, Experimental/veterinary , Time Factors , Whole-Body Irradiation
6.
Health Phys ; 92(4): 396-406, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17351505

ABSTRACT

The protection of the thyroid against radioiodine uptake has been an important safety concern for decades. After several studies examined potassium iodide blockade efficacy in the 1960's and 1970's, a standard dosage was prescribed by both the World Health Organization and the U.S. Food and Drug Administration. In this paper, we tested the effectiveness of a scaled version of that standard dosage in comparison to higher doses in mice. A novel gamma camera was employed with a high spatial resolution for precisely quantifying activity within the thyroid and a field of view large enough to image the entire mouse body. Thyroid and whole-body 125I biodistribution was analyzed immediately after exposure and 1 and 7 days later. It was found that 1 h after exposure five times the scaled human dose blocked thyroid uptake about 40% more effectively than the 1X scaled dose. Even after 1 d and 7 d, five times the recommended scaled human dose blocked approximately 10% more effectively than the 1X dose. These data suggest the need for continued evaluation of the effectiveness of KI as a blocking agent and the application of novel, non-invasive technologies to this important human health issue.


Subject(s)
Gamma Cameras , Iodine Radioisotopes/pharmacokinetics , Potassium Iodide/pharmacokinetics , Radiation Injuries, Experimental , Radiopharmaceuticals , Thyroid Gland/drug effects , Tissue Distribution/drug effects , Administration, Oral , Animals , Humans , Mice , Mice, Inbred C57BL , Potassium Iodide/administration & dosage , Radiation Injuries, Experimental/prevention & control , Radiation Injuries, Experimental/veterinary , Radiopharmaceuticals/pharmacokinetics , Radiopharmaceuticals/therapeutic use , Thyroid Gland/metabolism , Tissue Distribution/physiology , Whole-Body Counting
7.
Bone ; 36(2): 323-30, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15780959

ABSTRACT

Squamous cell carcinomas (SCC) of the upper aero-digestive tract are characterized by a high incidence of bone invasion; their treatment often requires large and damaging surgical resections and radiotherapy. Surgical and radiotherapeutic procedures generate irreversible effects on normal tissues, involving injuries on their reparation properties, especially on bone. The quality of life of patients undergoing major surgery and radiotherapy in maxillary and mandible areas is often reduced but could be improved by bone reconstructions. Bone reconstructions are rarely performed because surgery is complex and unsafe in irradiated bone. The aim of the study was to evaluate the bone reconstruction possibilities of macroporous biphasic calcium phosphate (MBCP) associated to autologous bone marrow (BM) graft injected after irradiation. MBCP hollowed blocks were specially designed and implanted in tibia and femur bone before irradiation in a dog model. Implants were removed after 18 weeks. This is the first report of experiments performed after radiation delivery using high fractionated doses approximating usual treatment of SCC in human. The quality of the bone adjacent to implanted MBCP and the bone ingrowth's rates were evaluated. The qualitative and quantitative role of BM grafts associated with the MBCP implants was determined, using scanning electron microscopy linked to quantitative image analysis. A direct contact between newly formed bone and MBCP implants associated to BM graft was observed, without fibrous interposition. The new-bone formation was statistically increased inside the MBCP (P=0.0126) by BM grafts. This study demonstrates that BM graft added to MBCP constitute an appropriate material to be considered in case of bone defect occurring in irradiated tissue, and could be foreseen for use after bone removal for oncologic obligations.


Subject(s)
Bone Marrow Transplantation/methods , Calcium Phosphates/administration & dosage , Radiation Injuries, Experimental/drug therapy , Radiation Injuries, Experimental/surgery , Animals , Bone Diseases/drug therapy , Bone Diseases/surgery , Bone Diseases/veterinary , Bone Marrow Transplantation/veterinary , Bone Regeneration/drug effects , Bone Regeneration/physiology , Dogs , Female , Microscopy, Electron, Scanning , Radiation Injuries, Experimental/veterinary , Transplantation, Autologous
8.
Am J Vet Res ; 40(8): 1057-61, 1979 Aug.
Article in English | MEDLINE | ID: mdl-525908

ABSTRACT

Promethazine (2 mg/kg), cimetidine (4 mg/kg), thiethylperazine (0.86 mg/kg), and naloxone (0.08 mg/kg) were each evaluated for their ability to increase the threshold of radiation-induced emesis in the dog. Each dog was fed a can of dog food (ca 0.4 kg) and then injected IM with the appropriate drug 1 hour before being irradiated by a 60Co teletherapy unit. The total radiation dose given an individual dog was determined by an up-and-down exposure schedule. Dogs were then observed continuously for 10 hours while the number, time of onset, and duration of each emetic episode were monitored. The dose of radiation causing emesis in 50% (ED50 +/- SEM) of control dogs was 170 +/- 38.5 rad. The ED50 +/- SEM was increased to 402 +/- 18.6 rad by promethazine, to 331 +/- 27.3 rad by cimetidine, and to 320 +/- 38.5 rad by thiethylperazine. This increased tolerance was significant at P less than 0.05 for each drug. The ED50 for naloxone was 262.5 +/- 92.9 rad, which was not a statistically significant increase in threshold.


Subject(s)
Cimetidine/therapeutic use , Dog Diseases/drug therapy , Guanidines/therapeutic use , Naloxone/therapeutic use , Promethazine/therapeutic use , Radiation Injuries/veterinary , Thiethylperazine/therapeutic use , Vomiting/veterinary , Animals , Chemoreceptor Cells/drug effects , Dogs , Male , Radiation Injuries, Experimental/complications , Radiation Injuries, Experimental/veterinary , Vomiting/drug therapy , Vomiting/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...